£300K
The Cambridge-based biotechnology company secured the capital from a group of angel investors and Finance Wales.
NB
Nemesis Bioscience
Nemesis Bioscience develops biological therapeutics to suppress antibiotic resistance.
Cambridge, UK—Founded 2014
£300KTotal raised
Nemesis Bioscience is a biotechnology company developing therapeutics to tackle antibiotic resistance.
Filed accounts
Cash at bank
Members only
Net current assets
Members only
Total assets less current liabilities
Members only
Net assets
Members only
Shareholders' funds
Members only
Fixed assets
Members only
Cash, assets and headcount from Nemesis Bioscience's latest Companies House filing — with year-on-year movement, free with a Winfred account.
Categories
Team
FM
Frank Massam
Chief executive
Frank previously served as chief executive of Nemesis Bioscience and chief operating officer of Population Genetics Technologies. He also held strategy and commercial roles at Agilent Technologies and Pharmagene.
LinkedIn